Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approval of Lyfgenia (lovotibeglogene autotemcel) for treatment of patients ages 12 and older with sickle cell disease and a history of vaso-occlusive events – bluebird bio

Written by | 12 Dec 2023

bluebird bio, Inc. announced the FDA has approved Lyfgenia (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages… read more.

EU approves Oxbryta for hemolytic anemia due to sickle cell disease – Global Blood Therapeutics

Written by | 29 Jun 2022

Global Blood Therapeutics announced the European Commission (EC) has granted Marketing Authorization for Oxbryta (voxelotor) for the treatment of hemolytic anemia due to sickle cell disease (SCD) in… read more.

Experimental gene therapy reverses sickle cell disease for years

Written by | 24 Dec 2021

A study of an investigational gene therapy for sickle cell disease has found that a single dose restored blood cells to their normal shape and eliminated the most… read more.

NICE (UK) recommends Adakveo as a treatment for preventing recurrent sickle cell crises – Novartis

Written by | 29 Oct 2021

Novartis is pleased to announce that eligible patients in England and Wales will soon have routine access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA). The news… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.